Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
April 04, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
March 30, 2017 11:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Achaogen Reports First Quarter 2016 Financial Results
May 05, 2016 16:05 ET
|
Achaogen, Inc.
-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017...